Please login to the form below
Amylyx
This page shows the latest Amylyx news and features for those working in and with pharma, biotech and healthcare.
Amylyx’s Relyvrio receives FDA approval for ALS treatment
Joshua Cohen and Justin Klee, co-chief executive officers of Amylyx said the approval was “an exciting milestone for the ALS community”. ... The European Medicines Agency is reviewing the company’s marketing authorisation application for Relyvrio
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest appointments
-
Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals
The founder and former chief executive officer of Biogen Dr Walter Gilbert has been elected to Amylyx Pharmaceuticals' board of directors. ... Justin Klee, co-founder and president of Amylyx, said: “Dr Gilbert brings an enormous breadth of experience
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest from PMHub
-
Evoke Mind+Matter
They include: Aerogen, Akcea, Allakos, Alexion, Amylyx Pharmaceuticals, Astellas, Baxter Healthcare, Bayer, Biocryst, Biogen, Biomarin, Bio-Oil, Boehringer Ingelheim, Cryoport, Colgate Palmolive, CSL Behring, Eiger BioPharmaceuticals, EIT Health,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Kite and Arcellx close multiple myeloma collaboration agreement
- The challenges of identifying rare diseases
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EU outlines measures to mitigate antibiotic shortage across Europe
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EC launches cancer imaging initiative to accelerate innovation and early diagnosis
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- The challenges of identifying rare diseases
- With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
